-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Professor Wang Fenghua and Professor Han Fei from Sun Yat-Sen University Cancer Center published a research result in JAMA Netw Open, mainly based on the POLARIS-02 study, to explore the role of plasma EBV DNA levels in recurrent or metastatic nasopharyngeal carcinoma (RM).
Recently, Professor Wang Fenghua and Professor Han Fei from Sun Yat-Sen University Cancer Center published a research result in JAMA Netw Open, mainly based on the POLARIS-02 study, to explore the role of plasma EBV DNA levels in recurrent or metastatic nasopharyngeal carcinoma (RM).
From December 22, 2016 to February 19, 2019, 279 patients with RM-NPC were screened in 17 participating centers nationwide; 190 patients were enrolled and followed up until February 19, 2020
From December 22, 2016 to February 19, 2019, 279 patients with RM-NPC were screened in 17 participating centers nationwide; 190 patients were enrolled and followed up until February 19, 2020
Of the 190 patients, 11 lacking baseline EBV DNA level data were excluded, and ultimately 179 patients with RM-NPC receiving anti-PD-1 therapy were included in the baseline analysis cohort, 148 (82.
Of the 190 patients, 11 lacking baseline EBV DNA level data were excluded, and ultimately 179 patients with RM-NPC receiving anti-PD-1 therapy were included in the baseline analysis cohort, 148 (82.
Among the 179 patients, taking EBV DNA 10 000 IU/mL as the cut-off point, 75 patients with EBV DNA below 10 000 IU/mL were in the low-level group, and 104 patients with EBV DNA above 10 000 IU/mL in the high-level group.
Among the 148 patients with dynamic detection of EBV DNA levels, patients were divided into 2 groups according to the ratio of week 4 (W4) to baseline: ≤0.
Among the 148 patients with dynamic detection of EBV DNA levels, patients were divided into 2 groups according to the ratio of week 4 (W4) to baseline: ≤0.
The DCB rate was significantly higher in patients with low baseline EBV DNA levels (n = 71) than in patients with high baseline EBV DNA levels (n = 97) (27 [38.
The DCB rate was significantly higher in patients with low baseline EBV DNA levels (n = 71) than in patients with high baseline EBV DNA levels (n = 97) (27 [38.
Among the 35 patients with complete remission, partial remission, and stable disease that eventually progressed, the increase in EBV DNA levels preceded imaging progression by a median of 2.
Among the 35 patients with complete remission, partial remission, and stable disease that eventually progressed, the increase in EBV DNA levels preceded imaging progression by a median of 2.
Taken together, our study demonstrates that plasma EBV DNA is a prognostic marker in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) receiving anti-PD-1 monotherapy and can be used to monitor disease progression
Taken together, our study demonstrates that plasma EBV DNA is a prognostic marker in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) receiving anti-PD-1 monotherapy and can be used to monitor disease progression
Original source:
Xu JY, Wei XL, Ren C, Zhang Y, Hu YF, Li JY, Chen JL, Wang YQ, Han F, Wang FH.
Xu JY, Wei XL, Ren C, Zhang Y, Hu YF, Li JY, Chen JL, Wang YQ, Han F, Wang FH.
Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti -Programmed Cell Death 1 Immunotherapy.
JAMA Netw Open.
2022 Mar 1;5(3):e220587.
doi: 10.
1001/jamanetworkopen.
2022.
0587.
PMID: 35230439; PMCID: PMC8889459.
Leave a comment here
